Treatment with depleting CD4 monoclonal antibody results in a preferential loss of circulating naive T cells but does not affect IFN-γ secreting TH1 cells in humans

Journal of Clinical Investigation

Volumn 99, Issue 9, 1997, Pages 2225-2231

  Rep, Martin H G ^a   Van Oosten, Bob W ^b   Roos, Marijke T L ^a   Adèr, Herman J ^c   Polman, Chris H ^b   Van Lier, René A W ^a,d  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

^d CENTRAL LABORATORY   (Netherlands)

Author keywords

autoimmune diseases therapy; CD4 antibodies, monoclonal; multiple sclerosis; T lymphocyte subsets; Thl cells

Indexed keywords

CD4 ANTIGEN; CD45 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 4; MONOCLONAL ANTIBODY CM T 412; OKT 4; UNCLASSIFIED DRUG;

ADULT; ARTICLE; AUTOIMMUNITY; CELL TYPE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HELPER CELL; HUMAN; HUMAN CELL; INTERFERON INDUCTION; LYMPHOCYTE COUNT; MALE; MULTIPLE SCLEROSIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; T LYMPHOCYTE SUBPOPULATION;

EID: 0030926207     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119396     Document Type: Article

References (59)

1. Brown, J.H., T.S. Jardetzky, J.C. Gorga, L.J. Stern, R.G. Urban, J.L. Strominger, and D.C. Wiley. 1993. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature (Lond.). 364:33-39.
2. Janeway, C.A.J., S. Carding, B. Jones, J. Murray, P. Portoles, R. Rasmussen, J. Rojo, K. Saizawa, J. West, and K. Bottomly. 1988. CD4+ T cells: specificity and function. Immunol. Rev. 101:39-80.
3. Banchereau, J., F. Bazan, D. Blanchard, F. Briere, J.P. Galizzi, C. Van Kooten, Y.J. Liu, F. Rousset, and S. Saeland. 1994. The CD40 antigen and its ligand. Annu. Rev. Immunol. 12:881-922.
4. Bottomly, K. 1988. A functional dichotomy in CD4+ T lymphocytes. Immunol. Today. 9:268-274.
5. Mosmann, T.R., and R.L. Coffman. 1989. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7:145-173.
6. Romagnani, S. 1991. Human TH1 and TH2 subsets: doubt no more. Immunol. Today. 12:256-257.
7. Seder, R.A., and W.E. Paul. 1994. Acquisition of lymphokine-producing phenotype by CD4+ T cells. Annu. Rev. Immunol. 12:635-673.
8. Druet, P., R. Sheela, and L. Pelletier. 1995. Th1 and Th2 cells in autoimmunity. Clin. Exp. Immunol. 101(Suppl. 1):9-12.
9. Charlton, B., and K.J. Lafferty. 1995. The Th1/Th2 balance in autoimmunity. Curr. Opin. Immunol. 7:793-798.
10. Zamvil, S.S., and L. Steinman. 1990. The T lymphocyte in experimental allergic encephalomyelitis. Annu. Rev. Immunol. 8:579-621.
11. Acha Orbea. H., L. Steinman, and H.O. McDevitt. 1989. T cell receptors in murinc autoimmune diseases. Annu. Rev. Immunol. 7:371-405.
12. Zamvil, S.S., D.J. Mitchell, M.B. Powell, K. Sakai, J.B. Rothbard, and L. Steinman. 1988. Multiple discrete encephalitogenic epitopes of the autoantigen myelin basic protein include a determinant for I-E class II-restricted T cells. J. Exp. Med. 168:1181-1186.
13. Brostoff, S.W., and D.W. Mason. 1984. Experimental allergic encephalomyelitis: successful treatment in vivo with a monoclonal antibody that recognizes T helper cells. J. Immunol. 133:1938-1942.
14. Waldor, M.K., S. Sriram, R. Hardy, L. A. Herzenberg, L. Lanier, M. Lim, and L. Steinman. 1985. Reversal of experimental allergic encephalomyelitis with monoclonal antibody to a T-cell subset marker. Science (Wash. DC). 227:415-417.
15. van Lambalgen, R., and M. Jonker. 1987. Experimental allergic encephalomyelitis in rhesus monkeys. II. Treatment of EAE with anti-T lymphocyte subset monoclonal antibodies. Clin. Exp. Immunol. 68:305-312.
16. van Lambalgen, R., and M. Jonker. 1987. Experimental allergic encephalomyelitis in rhesus monkeys. I. Immunological parameters in EAE resistant and susceptible rhesus monkeys. Clin. Exp. Immunol. 68:100-107.
17. Pelegri, C., M.P. Morante, C. Castellote, A. Franch, and M. Castell. 1996. Treatment with an anti-CD4 monoclonal antibody strongly ameliorates established rat adjuvant arthritis. Clin. Exp. Immunol. 103:273-278.
18. Williams, R.O., and A. Whyte. 1996. Anti-CD4 monoclonal antibodies suppress murine collagen-induced arthritis only at the time of primary immunization. Cell. Immunol. 170:291-295.
19. Reynolds, J., and C.D. Pusey. 1994. In vivo treatment with a monoclonal antibody to T helper cells in experimental autoimmune glomerulonephritis in the BN rat. Clin. Exp. Immunol. 95:122-127.
20. Tomer, Y., M. Blank, and Y. Shoenfeld. 1994. Suppression of experimental antiphospholipid syndrome and systemic lupus erythematosus in mice by anti-CD4 monoclonal antibodies. Arthritis Rheum. 37:1236-1244.
21. Kumar, V., and E.E. Sercarz. 1991. Regulation of autoimmunity. Curr. Opin. Immunol. 3:888-895.
22. Hutchings, P., N. Parish, L. O'Reilly, K. Dawe, I.M. Roitt, and A. Cooke. 1993. The regulation of autoimmunity through CD4+ T celts. Autoimmunity. 15(Suppl.):21-23.
23. Racadot, E., J. Wijdenes, and D. Wendung. 1992. Immunological follow-up of 17 patients with rheumatoid arthritis treated in vivo with an anti-T CD4+ monoclonal antibody (B-F5). Clin. Exp. Rheumatol. 10:365-374.
24. Moreland, L.W., R.P. Bucy, A. Tilden, P.W. Pratt, A.F. LoBuglio, M. Khazaeli, M.P. Everson, P. Daddona, J. Ghrayeb, C. Kilgarriff, et al. 1993. Use of a chimeric monoclonal anti-CD4 antibody in patients with refractory rheumatoid arthritis. Arthritis Rheum. 36:307-318.
25. van der Lubbe, P.A., C. Reiter, F.C. Breedveld, K. Kruger, M. Schatten-kirchner, M.E. Sanders, and G. Riethmüller. 1993. Chimeric monoclonal antibody cM-T412 as a therapeutic approach to rheumatoid arthritis. Arthritis Rheum. 10:1375-1379.
26. Hiepe, F., H.D. Volk, E. Apostoloff, R. von Baehr, and F. Emmrich. 1991. Treatment of severe systemic lupus erythematosus with anti-CD4 monoclonal antibody [letter]. Lancet. 338:1529-1530.
27. 26a. Stronkhorst, A., S. Radema, S.-L. Yong, H. Bijl, I.J.M. ten Berge, G.N.J. Tytgat, and S.J.H. van Deventer. 1997. CD4 antibody treatment in patients with active Crohn's disease. Gut. In press.
28. Racadot, E., L. Rumbach, M. Bataillard, J. Galmiche, J.L. Henlin, M. Truttmann, P. Herve, and J. Wijdenes. 1993. Treatment of multiple sclerosis with anti-CD4 monoclonal antibody. A preliminary report on B-F5 in 21 patients. J. Autoimmun. 6:771-786.
29. Lindsey, J.W., S. Hodgkinson, R. Mehta, R.C. Siegel, D.J. Mitchell, M. Lim, C. Piercy, T. Tram, L. Dorfman, D. Enzmann, et al. 1994. Phase 1 clinical trial of chimeric monoclonal anti-CD4 antibody in multiple sclerosis. Neurology. 44:413-419.
30. Lindsey, J.W., S. Hodgkinson, R. Mehta, D. Mitchell, D. Enzmann, and L. Steinman. 1994. Repeated treatment with chimeric anti-CD4 antibody in multiple sclerosis. Ann. Neurol. 36:183-189.
31. Choy, E.H., I.C. Chikanza, G.H. Kingsley, V. Corrigall, and G.S. Panayi. 1992. Treatment of rheumatoid arthritis with single dose or weekly pulses of chimaeric anti-CD4 monoclonal antibody. Scand. J. Immunol. 36:291-298.
32. Moreland, L.W., P.W. Pratt, M.D. Mayes, A. Postlethwaite, M.H. Weisman, T. Schnitzer, R. Lighlfoot, L. Calabrese, D.J. Zelinger, J.N. Woody, et al. 1995. Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate. Arthritis Rheum. 38:1581-1588.
33. Van Oosten, B.W., M. Lai, S. Hodgkinson, F. Barkhof, D.H. Miller, I.F. Moseley, A.J. Thompson, P. Rudge, A. McDougall, J.G. McLeod, et al. 1997. Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial. Neurology. In press.
34. Van Oosten, B.W., M. Lai, F. Barkhof, D.H. Miller, I.F. Moseley, A.J. Thompson, S. Hodgkinson, and C.H. Polman. 1996. A phase II trial of anti-CD4 antibodies in the treatment of multiple sclerosis. Multiple Sclerosis. 1:339-342.
35. Van Kemenade, F.J., E. Tellegen, M.M. Maurice, A.C. Lankester, T.W. Kuijpers, M. Brouwer, R. De Jong, F. Miedema, and R.A. van Lier. 1994. Simultaneous regulation of CD2 adhesion and signaling functions by a novel CD2 monoclonal antibody. J. Immunol. 152:4425-4432.
36. Jung, T., U. Schauer, C. Heusser, C. Neuman, and C. Rieger. 1993. Detection of intracellular cytokines by flow cytometry. J. Immunol. Methods. 159: 197-207.
37. Hamann, D., P.A. Baars, B. Hooibrink, and R.A.W. Van Lier. 1996. Heterogeneity of the human CD4+ T-cell population: two distinct CD4+ T-cell subsets characterized by coexpression of CD45RA and CD45R0 isoforms. Blood. 9:3513-3521.
38. Schellekens, P.T., M.T. Roos, F. De Wolf, J.M. Lange, and F. Miedema. 1990. Low T-cell responsiveness to activation via CD3/TCR is a prognostic marker for acquired immunodeficiency syndrome (AIDS) in human immunodeficiency virus-1 (HIV-1)-infected men. J. Clin. Immunol. 10:121-127.
39. Gruters, R.A., F.G. Terpstra, R.E. De Goede, J.W. Mulder, F. De Wolf, P.T. Schellekens, R.A. van Lier, M. Tersmette, and F. Miedema. 1991. Immunological and virological markers in individuals progressing from seroconversion to AIDS. AIDS. 5:837-844.
40. Rep, M.H.G., R.Q. Hintzen, C.H. Polman, and R.A. van Lier. 1994. Functional defects in peripheral blood T cells of multiple sclerosis patients. Diminished in vitro responsiveness in accessory cell dependent activation systems. J. Neuroimmunol. 52:139-146.
41. Sanders, M.E., M.W. Makgoba, and S. Shaw. 1988. Human naive and memory T cells: reinterpretation of helper-inducer and suppressor-inducer subsets. Immunol. Today. 9:195-199.
42. Hintzen, R.Q., R. De Jong, S.M.A. Lens, M. Brouwer, P. Baars, and R.A.W. Van Lier. 1993. Regulation of CD27 expression on subsets of mature T-lymphocytes. J. Immunol. 151:2426-2435.
43. Picker, L.J., M.K. Singh, Z. Zdraveski, J.R. Treer, S.L. Waldrop, P.R. Bergstresser, and V.C. Maino. 1995. Direct demonstration of cytokine synthesis heterogeneity among human memory/effector T cells by flow cytometry. Blood. 86:1408-1419.
44. Rice, J.C., and R.P. Bucy. 1995. Differences in the degree of depletion, rate of recovery, and the preferential elimination of naive CD4+ T cells by anti-CD4 monoclonal antibody (GK1.5) in young and aged mice. J. Immunol. 154:6644-6654.
45. Mackall, C.L., T.A. Fleisher, M.R. Brown, M.P. Andrich, C.C. Chen, I.M. Feuerstein, M.E. Horowitz, I.T. Magrath, A.T. Shad, S.M. Steinberg, et al. 1995. Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N. Engl. J. Med. 332:143-149.
46. Margolick, J.B., A.D. Donnenberg, A. Munoz, L.P. Park, K.D. Bauer, J.V. Giorgi, J. Ferbas, and A.J. Saah. 1993. Changes in T and non-T lymphocyte subsets following seroconversion to HIV-1: stable CD3+ and declining CD3-populations suggest regulatory responses linked to loss of CD4 lymphocytes. The Multicenter AIDS Cohort Study. J. Acquir. Immune Defic. Syndr. 6:153-161.
47. Adleman, L.M., and D. Wofsy. 1993. T-cell homeostasis: implications in HIV infection [comment]. J. Acquir. Immune Defic. Syndr. 6:144-152.
48. Tough, D.F., P. Borrow, and J. Sprent. 1996. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science (Wash. DC). 272:1947-1950.
49. Wang, Z.Q., A. Dudhane, T. Orlikowsky, K. Clarke, X. Li, Z. Darzyn-kiewicz, and M.K. Hoffmann. 1994. CD4 engagement induces Fas antigen-dependent apoptosis of T cells in vivo. Eur. J. Immunol. 24:1549-1552.
50. Desbarats, J., J.H. Freed, P.A. Campbell, and M.K. Newell. 1996. Fas (CD95) expression and death-mediating function are induced by CD4 cross-linking on CD4+ T cells. Proc. Natl. Acad. Sci. USA. 93:11014-11018.
51. Jamali, I., E.H. Field, A. Fleming, and J.S. Cowdery. 1992. Kinetics of anti-CD4-induced T helper cell depletion and inhibition of function. Activation of T cells by the CD3 pathway inhibits anti-CD4-mediated T cell elimination and down-regulation of cell surface CD4. J. Immunol. 148:1613-1619.
52. Wang, Z.Q., A. Dudhane, T. Orlikowsky, and M.K. Hoffmann. 1995. T cell antigen receptor engagement abrogates CD4-mediated T cell deletion in vivo. Int. Immunol. 7:207-211.
53. Krammer, P.H., I. Behrmann, P. Daniel, J. Dhein, and K.M. Debatin. 1994. Regulation of apoptosis in the immune system. Curr. Opin. Immunol. 6: 279-289.
54. Chace, J.H., J.S. Cowdery, and E.H. Field. 1994. Effect of anli-CD4 on CD4 subsets. I. Anti-CD4 preferentially deletes resting, naive CD4 cells and spares activated CD4 cells. J. Immunol. 152:405-412.
55. van der Lubbe, P.A., B.A.C. Dijkmans, H.M. Markusse, U. Nassander, and F.C. Breedveld. 1995. A randomized double-blind placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis. Arthritis Rheum. 38:1097-1106.
56. Howie, S.E., A.J. Sommerfield, E. Gray, and D.J. Harrison. 1994. Peripheral T lymphocyte depletion by apoptosis after CD4 ligation in vivo: selective loss of CD44- and "activating" memory T cells. Clin. Exp. Immunol. 95: 195-200.
57. O'Neill, J.K., D. Baker, A.N. Davison, S.J. Alien, C. Butter, H. Waldmann, and J-L. Turk. 1993. Control of immune-mediated disease of the central nervous system with monoclonal (CD4-specific) antibodies. J. Neuroimmunol. 45:1-14.
58. Ranges, O.E., S. Sriram, and S.M. Cooper. 1985. Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4. J. Exp. Med. 162:1105-1110.
59. Hom, J.T., L.D. Butler, P.E. Riedl, and A.M. Bendele. 1988. The progression of the inflammation in established collagen-induced arthritis can be altered by treatments with immunological or pharmacological agents which inhibit T cell activities. Eur. J. Immunol. 18:881-888.